Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5640_Библиотеки_им_академика_М_И_Перельмана.pdf
Nanotechnology in Drug Delivery: From Bench to Bedside 79
utilized in drug delivery, antioxidants, and organic photovoltaics
35, 36]. Carbon nanotubes, cylindrical nanostructures composed
[
of rolled-up graphene sheets, exhibit extraordinar
strength and electrical conductivity, making them ideal for applications in composites, electronics, and sensors. Graphene, a single
layer of carbon atoms arranged in a two-dimensional hexagonal
lattice, is renowned for its exceptional strength, flexibility, and
conductivity. Graphene and its derivatives find applications in flexible el
ectronics, energy storage devices, and membranes for water
purification. Carbon-based nanoparticles hold immense
in advancing technologies related to electronics, energy, and materials science [
37]
.
4 Nanotechnology-Based Drug Delivery Systems
Nanotechnology-based drug delivery systems represent a cuttingedge approach to enhancing the efficacy, specificity, and safety of
therapeutic agents. These systems leverage the unique properties of
nanoparticles to overcome limitations associated with conventional
drug delivery methods [
nanotechnology-based drug delivery systems.
38]. Below, there are four key types of
y mechanical
potential
4.1 Smart Drug Delivery Systems
4.2 Polymer–Drug
Conjugates
Smart drug delivery systems are designed to respond to specific
stimuli in the body, such as pH, temperature, enzymes, or external
triggers like light or magnetic fields [
39]. By incorporating stimuli-
responsive materials into nanoparticles, researchers can achieve
controlled drug release at the target site, minimizing off-target
effects and improving therapeutic outcomes. For example,
pH-responsive nanoparticles can release drugs selectively in acidic
environments, such as tumor tissues, exploiting the pH gradient
between diseased and healthy tissues [
40]. Similarly, temperature-
sensitive nanoparticles can release drugs in response to changes in
temperature associated with inflammation or infection sites. Smart
drug delivery systems offer precise spatiotemporal control over
drug release, optimizing therapeutic efficacy while minimizing
side effects [
41].
Polymer–drug conjugates involve covalent attachment of therapeutic agents to polymer chains, forming macromolecular prodrugs.
This approach offers several advantages, including improved solubility, stability, and bioavailability of drugs, as well as controlled
release profiles. Polymer–drug conjugates can be engineered to
target specific tissues or cells by incorporating targeting ligands or
responsive moieties into the polymer backbone [
3, 42]. Addition-
ally, these conjugates can bypass multidrug resistance mechanisms,
enhancing the effectiveness of chemotherapy agents. Examples of
polymer–drug conjugates include polyethylene glycol (PEG)–
80 Mounil Mankad et al.
doxorubicin conjugates, which exhibit prolonged circulation times
and reduced cardiotoxicity compared to free doxorubicin.
Polymer–drug conjugates represent a versatile platform for delivering a wide range of therapeutic agents, including small molecules,
peptides, and nucleic acids [
43].
4.3 Multifunctional Drug Carriers
4.4 Organic/ Inorganic Composites
Multifunctional drug carriers integrate multiple functionalities into
a single nanoparticle platform, enabling synergistic effects and
enhanced therapeutic outcomes [
44]. These carriers typically com-
bine dr ug delivery capabilities with diagnostic, imaging, or targeting functionalities to achieve personalized and precise treatments.
For instance, nanoparticles can be engineered to simultaneously
deliver chemotherapeutic drugs while imaging tumor tissues
using contrast agents or targeting ligands. Additionally, multifunctional drug carriers can incorporate stimuli-responsive elements to
enable triggered drug release in response to specific biological cues.
By integrating multiple functionalities into a single platform, these
carriers offer a comprehensive solution for diagnosing and treating
diseases, particularly cancer [
45, 46].
Organic/inorganic composites combine organic polymers with
inorganic nanoparticles to leverage the unique properties of both
materials [47]. These composites exhibit synergistic effects, such as
enhanced stability, biocompatibility, and functionality, making
them ideal candidates for drug delivery applications. For example,
silica-based nanoparticles can be coated with biocompatible polymers to improve their colloidal stability and biocompatibility while
enabling controlled drug release [
48]. Similarly, gold nanoparticles
can be functionalized with polymers to enhance their targeting
specificity and payload capacity for cancer therapy. Organic/inorganic composites offer a versatile platform for designing customized drug delivery systems with tailored properties and
functionalities [
49].
5 Nanoparticulate Drug Delivery Systems
Nanoparticulate drug delivery systems have revolutionized the field
of pharmaceuticals by offering precise control over drug release
kinetics, improved targeting capabilities, and enhanced therapeutic
efficacy. Among the various nanoparticulate drug delivery systems,
liposomes, microemulsions, and nanoparticles stand out as versatile
platforms with diverse applications [
5.1 Liposomes
Liposomes are spherical vesicles composed of lipid bilayers, which
enclose an aqueous core. These versatile nanocarriers can encapsulate hydrophilic drugs within their aqueous core and hydrophobic
drugs within their lipid bilayers, making them ideal for delivering a
50, 51].
Nanotechnology in Drug Delivery: From Bench to Bedside 81
wide range of therapeutics [52]. Liposomes can be engineered to
vary in size, surface charge, lipid composition, and membrane
permeability, enabling customization for specific applications.
One of the key advantages of liposomes is their ability to improve
the pharmacokinetics of drugs by enhancing their solubility, stability, and bioavailability [
nalized with targeting ligands
53
]. Moreover, liposomes can be functio-
or stimuli-responsive moieties to
achieve site-specific drug delivery and controlled release. Clinically
approved liposomal formulations, such as Doxil® and AmBisome®, have demonstrated significant benefits in cancer therapy
and antifungal treatment, respectively. Overall, liposomes represent
a versatile and clinically validated drug delivery platform with
immense potential for improvi
ng therapeutic outcomes [
54].
5.2 Microemulsions
5.3 Nanoparticles
Microemulsions are thermodynamically stable colloidal dispersions
of oil, water, surfactants, and cosurfactants, typically ranging in size
from 10 to 100 nm. These nanostructured systems offer advantages
such as high drug-loading capacity, ease of preparation, and
enhanced bioavailability of poorly soluble drugs. Microemulsions
can solubilize both hydrophobic and hydrophilic drugs, facilitating
their absorption and transport across biological barriers
55, 56].
[
Moreover
, microemulsions can be formulated as transparent or translucent systems, enabling various routes of administration including oral, topical, and parenteral. The small droplet size
and large interfacial area of microemulsions facilitate rapid dr ug
release and uptake, making them promising candidates for targeted
drug delivery and sustained release applications. Despite their
potential, challenges such as stability, sterilization, and scale-up
remain to be addressed for widespread clinical translation of
microemulsion-based drug delivery systems [
57].
Nanoparticles refer to solid colloidal particles with sizes typically
ranging from 1 to 1000 nm, composed of various materials including polymers, lipids, metals, and inorganic substances [58]. These
nanoparticles offer a versatile platform for delivering therapeutic
agents with precise control over drug release kinetics and targeting
specificity. Polymeric nanoparticles, such as poly(lactic-co-glycolic
acid) (PLGA) nanoparticles, offer advantages such as biocompatibility, tunable degradation rates, and sustained drug release profiles
59].
[
Lipid nanoparticles, including solid lipid nanoparticles
(SLNs) and nanostructured lipid carriers (NLCs), combine the
advantages of liposomes with improved stability and scalability.
Inorganic nanoparticles, such as gold nanoparticles and iron oxide
nanoparticles, exhibit unique physical and chemical properties that
can be exploited for imaging, diagnostics, and therapeutic applications. Nanoparticles can be surface-functionalized with targeting
ligands, antibodies, or peptides to achieve active targeting of diseased tissues or cells. Additionally, stimuli-responsive nanoparticles
82 Mounil Mankad et al.
can enable triggered drug release in response to specific biological
cues, enhancing therapeutic efficacy while minimizing off-target
effects. Nanoparticle-based drug delivery systems have shown
promise in a wide range of applications, including cancer therapy,
infectious diseases, neurological disorders, and regenerative
medicine [
6 Applications
The application of nanotechnology in dr ug delivery has transformed the landscape of pharmaceuticals by offering novel
approaches to enhance the therapeutic efficacy, specificity, and
safety of drugs [
leverage the unique properties of nanoparticles to overcome challenges associated with conventional drug delivery methods, such as
poor solubility, low bioavailability, off-target effects, and systemic
toxicity [
60].
4]. Nanotechnology-enabled drug deliver y systems
61].
6.1 Enhanced Drug Delivery
6.2 Overcoming Biological Barriers
6.3 Controlled Drug Release
Nanotechnology offers precise control over drug release kinetics,
enabling sustained release, targeted delivery, and site-specific accumulation of therapeutic agents [62]. Nanoparticles can encapsulate
drugs within their core, protecting them from degradation and
facilitating their transport across biological barriers [61]. Moreover,
nanoparticles can be surface-functionalized with targeting ligands,
antibodies, or peptides to achieve active targeting of diseased tissues
or cells, while minimizing off-target effects on healthy tissues. This
enhanced drug delivery approach improves the therapeutic index of
drugs, allowing for lower doses and reduced side effects [
63].
Nanoparticles possess unique physicochemical properties that
enable them to overcome biological barriers such as the blood–
brain barrier (BBB), gastrointestinal epithelium, and mucus layers.
Nanoparticle-based drug delivery systems can bypass or penetrate
these barriers, allowing for targeted delivery of therapeutics to
specific organs or tissues [
64, 65]. For example, polymeric nano-
particles can be engineered to enhance oral drug absorption by
improving mucosal penetration and cellular uptake in the gastrointestinal tract. Similarly, lipid-based nanoparticles can facilitate drug
transport across the BBB for the treatment of neurological
disorders [
66].
Nanotechnology enables precise control over drug release profiles,
allowing for tailored drug delivery kinetics and spatiotemporal
modulation of drug concentrations. Stimuli-responsive nanoparticles can release drugs in response to specific environmental cues
such as pH, temperature, enzymes, or light, enabling triggered
drug release at the target site [
67, 68]. For instance, pH-sensitive
Nanotechnology in Drug Delivery: From Bench to Bedside 83
nanoparticles can release drugs selectively in acidic environments,
such as tumor tissues, exploiting the pH gradient between diseased
and healthy tissues. This controlled release capability enhances
therapeutic efficacy while minimizing systemic exposure and associated toxicities [
69, 70].
6.4 Combination Therapy
6.5 Personalized Medicine
Nanotechnology facilitates the codelivery of multiple therapeutic
agents, enabling combination therapy approaches to treat complex
diseases such as cancer, infectious diseases, and inflammatory disorders [
42]. Nanoparticle-based drug delivery systems can encap-
sulate different drugs with varying physicochemical properties
within a single carrier, allowing for synergistic effects and improved
therapeutic outcomes. Moreover, nanoparticles can codeliver drugs
with diagnostic agents or imaging contrast agents, enabling realtime monitoring of treatment response and disease
progression [
71].
Nanotechnology offers opportunities for personalized medicine by
tailoring drug delivery systems to individual patient characteristics
and disease profiles [72]. Nanoparticle-based drug delivery platforms can be customized in terms of size, shape, surface chemistry,
and drug-loading capacity to meet specific therapeutic needs
73, 74]. Furthermore, advances in nanomedicine enable the devel-
[
opment of companion diagnostics and theranostic platforms,
allowing for targeted drug delivery guided by patient-specific biomarkers or imaging modalities. This personalized approach holds
promise for optimizing treatment outcomes, minimizing adverse
effects, and improving patient adherence [
75].
7 Limitations
7.1 Complexity and Cost
While nanotechnology holds immense promise for revolutionizing
drug delivery and improving therapeutic outcomes, it is important
to acknowledge and address the limitations and challenges associated with its application in this field [
76]. Some of the key limita-
tions of nanotechnology in drug delivery include the following.
The development and manufacturing of nanotechnology-based
drug delivery systems can be complex and costly [
77]. The synthe-
sis, characterization, and scale-up of nanoparticles require
specialized equipment, expertise, and resources, which may pose
challenges for academic researchers and pharmaceutical companies.
Additionally, the regulatory approval process for nanomedicines
can be lengthy and expensive, further adding to the overall cost of
development and commercialization [
78, 79].
84 Mounil Mankad et al.
7.2 Biocompatibility and Toxicity
7.3 Stability and Shelf Life
7.4 Drug Loading and Release
While nanoparticles offer unique properties and functionalities,
concerns regarding their biocompatibility and potential toxicity
remain a significant challenge [80]. Certain nanoparticles may elicit
immune responses, cause inflammation, or induce cytotoxic effects,
leading to adverse reactions in vivo. Moreover, the long-term
effects of nanoparticle exposure on human health and the environment are not fully understood, necessitating comprehensive safety
assessments and risk evaluations [
81].
Nanoparticles are susceptible to aggregation, degradation, and
instability under physiological conditions, which can compromise
their efficacy and shelf life. Factors such as pH, temperature,
humidity, and storage conditions can impact the stability of nanoparticles and affect their performance over time [
82]. Strategies to
improve the stability and shelf life of nanotechnology-based drug
delivery systems, such as surface modifications, encapsulation techniques, and lyophilization, are actively being pursued [
1].
Achieving optimal drug-loading capacity and controlled release
kinetics is essential for the efficacy of nanotechnology-based drug
delivery systems. However, certain drugs may exhibit poor solubility, low encapsulation efficiency, or premature release from nanoparticles, limiting their therapeutic potential. Furthermore,
achieving precise control over drug release profiles, especially in
response to specific stimuli or biological cues, remains a challenge
that requires further research and optimization [
83, 84].
7.5 Biological Barriers and Clearance
8 Conclusions
Nanoparticles face several biological barriers in vivo, including the
reticuloendothelial system (RES), renal clearance, and blood–brain
barrier (BBB), which can hinder their distribution and accumulation at the target site [
85]. Strategies to evade or overcome these
barriers, such as surface modifications, stealth coatings, and targeted delivery approaches, are essential for enhancing the efficacy of
nanotechnology-based drug delivery systems. Additionally, the
clearance of nanoparticles from the body via renal excretion or
hepatic metabolism can limit their circulation time and therapeutic
efficacy [
86].
The integration of nanotechnology into drug delivery systems
represents a significant advancement with profound implications
for healthcare. By leveraging the unique properties of nanoparticles, nanotechnology offers solutions to overcome the limitations
of traditional drug delivery approaches, including poor bioavailability, off-target effects, and systemic toxicity. Through precise control
over drug release kinetics and enhanced targeting capabilities,
References
Nanotechnology in Drug Delivery: From Bench to Bedside 85
nanotechnology-based drug delivery systems hold promise for
improving therapeutic efficacy while minimizing side effects. The
evolution of nanomedicine from its inception to the present reflects
a trajectory of innovation driven by interdisciplinar y collaboration
and technological advancements. However, challenges such as
complexity, biocompatibility, stability, and regulatory considerations underscore the need for continued research and development
i
n this field. Despite these challenges, the application of nanotechnology in drug delivery has already demonstrated transformative
potential, offering novel approaches to enhance drug delivery,
overcome biological barriers, and enable personalized medicine.
As research progresses
and technologies evolve, nanotechnology
is poised to play an increasingly pivotal role in shaping the future
of pharmaceuticals and healthcare delivery.
1. Mishra M, Kumar P, Rajawat JS, Malik R,
Sharma G, Modgil A (2018) Nanotechnology:
revolutionizing the science of drug delivery.
Curr Pharm Des 24(43):5086–5107
2. Madaan T, Pandey S, Talegaonkar S, Delhi N
(2015) Nanotechnology: a smart drug delivery
tool in modern healthcare. J Chem Pharm Res
7(6):257–264
3. Gao Y, Xie J, Chen H, Gu S, Zhao R, Shao J,
Jia L (2014) Nanotechnology-based intelligent
drug design for cancer metastasis treatment.
Biotechnol Adv 32(4):761–777
4. Patra JK, Das G, Fraceto LF, Campos EV,
Rodriguez-Torres MD, Acosta-Torres LS,
Diaz-Torres LA, Grillo R, Swamy MK,
Sharma S, Habtemariam S (2018) Nano
based drug delivery systems: recent developments and future prospects. J Nanobiotechnol
16:1–33
5. Varala R, Kotra V, Kanuri AK, Burra MR, Nyamathullah S (2023) Nano drug deliverybenefits, limitations and future perspective.
Nano Med Mater 3(2):244
6. Subhan MA, Yalamarty SS, Filipczak N,
Parveen F, Torchilin VP (2021) Recent
advances in tumor
cancer treatment. J Personal Med 11(6):571
7. Manzari MT, Shamay Y, Kiguchi H, Rosen N,
Scaltriti M, Heller DA (2021) Targeted drug
delivery strategies for precision medicines. Nat
Rev Mater 6(4):351–370
8. Murday JS, Siegel RW, Stein J, Wright JF
(2009) Translational nanomedicine: status
assessment and opportunities. Nanomedicine
5(3):251–273
targeting via
EPR effect for
9. Decuzzi P, Peer D, Di Mascolo D, Palange AL,
Manghnani PN, Moghimi SM, Farhangrazi
ZS, Howard KA, Rosenblum D, Liang T,
Chen Z (2020) Roadmap on nanomedicine.
Nanotechnology 32(1):012001
10. Harrington KJ, Lewanski C, Northcote AD,
Whittaker J, Peters AM, Vile RG, Stewart JS
(2001) Phase II study of pegylated liposomal
doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer
of the head and neck. Eur J Cancer 37(16):
2015–2022
11. Fanfair D, Desai S, Kelty C (2007) The early
history of nanotechnology. Connexions 6:1–5
12. Vauthier C, Dubernet C, Chauvierre C,
Brigger I, Couvreur P (2003) Drug delivery
to resistant tumors: the potential of poly (alkyl
cyanoacrylate) nanoparticles. J Control Release
93(2):151–160
13. Shinto Y, Uchida A, Korkusuz F, Araki N, Ono
K (1992) Calcium hydroxyapatite ceramic used
as a delivery system for antibiotics. J Bone Joint
Surg British Vol 74(4):600–604
14. Lukowski G, Mu¨ller RH, Mu¨ ller BW, Dittgen
M (1993) Acrylic acid copolymer nanoparticles
for drug delivery. Part II: Characterization of
nanoparticles surface-modified by adsorption
of ethoxylated surfactants. Colloid Polym Sci
271:100–105
15. Cavallaro G, Fresta M, Giammona G,
Puglisi G, Villari A. Entrapment of β-lactams
antibiotics in polyethylcyanoacrylate nanoparticles: studies on the possible in vivo application
of this colloidal delivery system. Int J Pharm
1994;111(1):31–41
86 Mounil Mankad et al.
16. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li
C (2008) Nasal absorption enhancement of
insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm 68(3):526–534
17. Calvo P, Gouritin B, Chacun H, Desmaele D,
D’Angelo J, Noel JP, Georgin D, Fattal E,
Andreux JP, Couvreur P (2001) Longcirculating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Pharm Res 18:1157–1166
18. Paciotti GF, Kingston DG, Tamarkin L (2006)
Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional
tumor-targeted drug delivery vectors. Drug
Dev Res 67(1):47–54
19. Yu D, Xiao S, Tong C, Chen L, Liu X (2007)
Dialdehyde starch nanoparticles: preparation
and application in drug carrier. Chin Sci Bull
52:2913–2918
20. Rosenholm JM, Peuhu E, Bate-Eya LT, Eriksson JE, Sahlgren C, Linde´n M (2010) Cancercell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery
vectors. Small 6(11):1234–1241
21. Jadoun S, Arif R, Jangid NK, Meena RK
(2021) Green synthesis of nanoparticles using
plant extracts: a review. Environ Chem Lett
19(1):355–374
22. Urba´n P, Ranucci E, Ferna`ndez-Busquets X
(2015) Polyamidoamine nanoparticles as
nanocarriers for the drug delivery to malaria
parasite stages in the mosquito vector. Nanomedicine 10(22):3401–3414
23. Lamichhane TN, Raiker RS, Jay SM (2015)
Exogenous DNA loading into extracellular
vesicles via electroporation is size-dependent
and enables limited gene delivery. Mol Pharm
12(10):3650–3657
24. Garg U, Chauhan S, Nagaich U, Jain N (2019)
Current advances in chitosan nanoparticlesbased drug delivery and targeting. Adv Pharma
Bull 9(2):195
25. Ghaz-Jahanian MA, Abbaspour-Aghdam F,
Anarjan N, Berenjian A, Jafarizadeh-Malmiri
H (2015) Application of chitosan-based nanocarriers in tumor-targeted drug delivery. Mol
Biotechnol 57:201–218
26. Shariatinia Z (2022) Inorganic material-based
nanocarriers for delivery of biomolecules.
Nanoeng Biomater 14:245–293
27. Khan Y, Sadia H, Ali Shah SZ, Khan MN, Shah
AA, Ullah N, Ullah MF, Bibi H, Bafakeeh OT,
Khedher NB, Eldin SM (2022) Classification,
synthetic, and characterization approaches to
nanoparticles, and their applications in various
fields of nanotechnology: a review. Catalysts
12(11):1386
28. Sannino D (2021) Types and classification of
nanomaterials. In: Nanotechnology: trends
and future applications, pp 15–38
29. Napier ME, DeSimone JM (2007) Nanoparticle drug delivery platform. J Macromol Sci
Polym Rev 47(3):321–327
30. Fang F, Li M, Zhang J, Lee CS (2020) Different strategies for organic nanoparticle preparation in biomedicine. ACS Mater Lett 2(5):
531–549
31. Kumar R, Lal S. Synthesis of organic nanoparticles and their applications in drug delivery
and food nanotechnology: a review. J Nanomater Mol Nanotechnol 3 11:2
32. Paul W, Sharma CP (2020) Inorganic nanoparticles for targeted drug delivery. Biointegr Med
Implant Mater 1:333–373
33. Zhao MX, Zeng EZ, Zhu BJ (2015) The
biological applications of inorganic nanoparticle drug carriers. ChemNanoMat 1(2):82–91
34. Wang F, Li C, Cheng J, Yuan Z (2016) Recent
advances on inorganic nanoparticle-based cancer therapeutic agents. Int J Environ Res Public
Health 13(12):1182
35. Debnath SK, Srivastava R (2021) Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. Front
Nanotechnol 3:644564
36. Pardo J, Peng Z, Leblanc RM (2018) Cancer
targeting and drug delivery using carbon-based
quantum dots and nanotubes. Molecules
23(2):378
37. Oh WK, Yoon H, Jang J (2010) Size control of
magnetic carbon nanoparticles for drug delivery. Biomaterials 31(6):1342–1348
38. Lv Y, Li W, Liao W, Jiang H, Liu Y, Cao J,
Lu W, Feng Y (2024) Nano-drug delivery systems based on natural products. Int J Nanomedicine 31:541–569
39. Suri SS, Fenniri H, Singh B (2007)
Nanotechnology-based drug delivery systems.
Journal of occupational medicine and toxicology 2:1–6
40. Sharma D, Sharma N, Pathak M, Agrawala PK,
Basu M, Ojha H (2018) Nanotechnologybased drug delivery systems: challenges and
opportunities. Drug Target Stimuli Sens Drug
Deliv Syst 1:39– 79
41. Calixto G, Bernegossi J, Fonseca-Santos B,
Chorilli M (2014) Nanotechnology-based
drug deliver y systems for treatment of oral cancer: a review. Int J Nanomedicine 8:3719–
3735
42. Parhi P
Nanotechnology-based combinational drug
delivery: an emerging approach for cancer
, Mohanty C, Sahoo SK (2012)
Nanotechnology in Drug Delivery: From Bench to Bedside 87
therapy. Drug Discov Today 17(17–18):
1044–1052
43. Manandhar S, Sjo¨holm E, Bobacka J, Rosenholm JM, Bansal KK (2021) Polymer-drug
conjugates as nanotheranostic agents. J Nanother 2(1):63–81
44. Hsu JF, Chu SM, Liao CC, Wang CJ, Wang
YS, Lai MY, Wang HC, Huang HR, Tsai MH
(2021) Nanotechnology and
based drug delivery as the potential therapeutic
strategy for glioblastoma multiforme: an
update. Cancers 13(2):195
45. Li C, Wang Z, Lei H, Zhang D (2023) Recent
progress in nanotechnology-based drug carriers for resveratrol delivery. Drug Deliv
30(1):2174206
46. Gonza´lez LF, Bevilacqua LE, Naves R (2021)
Nanotechnology-based drug delivery strategies
to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases. Pharmaceutics 13(12):2055
47. Sivodia C, Sinha A (2022) Nanotechnology for
water treatment: recent advancement in the
remediation of organic and inorganic compounds. Nanotechnol Environ Remed 26:45–
57
48. Tripathy M, Aparajita P, Pattnayak S, Hota G,
Ghosh AK (2024, Jan 1) Nanotechnologybased sustainable approaches for remediation
of organic and inorganic pollutants from aqueous medium. In: Water, the environment and
the sustainable development goals
(pp 327 –355). Elsevier
49. Zhou S, Wu L (2009) Development of
nanotechnology-based organic coatings.
Compos Interfaces 16(4–6):281–292
50. Elumalai K, Srinivasan S, Shanmugam A
(2024) Review of the efficacy of nanoparticlebased drug delivery systems for cancer treatment. Biomed Technol 5:109–122
51. Yusuf A, Almotairy AR, Henidi H, Alshehri
OY, Aldughaim MS (2023) Nanoparticles as
Drug Deliver y Systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems.
Polymers 15(7):1596
52. Al-Jamal WT, Kostarelos K (2011) Liposomes:
from a clinically established drug delivery system to a nanoparticle platform for theranostic
nanomedicine. Acc Chem Res 44(10):
1094–1104
53. Allen TM, Cullis PR (2013) Liposomal drug
delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36–48
54. Samad A, Sultana Y, Aqil M (2007) Liposomal
drug delivery systems: an update review. Curr
Drug Deliv 4(4):297–305
nanocarrier-
55. Fanun M (2012) Microemulsions as delivery
systems. Curr Opin Colloid Interface Sci
17(5):306–313
56. Lawrence MJ, Rees GD (2000)
Microemulsion-based media as novel drug
delivery systems. Adv Drug Deliv Rev 45(1):
89–121
57. Ghosh PK, Murthy RS (2006) Microemulsions: a potential drug delivery system. Curr
Drug Deliv 3(2):167–180
58. Thassu D, Pathak Y, Deleers M (2007) Nanoparticulate drug-delivery systems: an overview.
Nanopart Drug Deliv Syst 30:1–31
59. Narang A, Chang RK, Hussain MA (2013)
Pharmaceutical development and regulatory
considerations for nanoparticles and nanoparticulate drug delivery systems. J Pharm Sci
102(11):3867–3882
60. Wilczewska AZ, Niemirowicz K, Markiewicz
KH, Car H (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64(5):1020–1037
61. Saeedi M, Eslamifar M, Khezri K, Dizaj SM
(2019) Applications of nanotechnology in
drug delivery to the central nervous system.
Biomed Pharmacother 111:666–
62. McDonald TA, Siccardi M, Moss D,
Liptrott N, Giardiello M, Rannard S, Owen A
(2015, Jan 1) The application of nanotechnology to drug delivery in medicine. In: Nanoengineering (pp 173–223). Elsevier
63. Luo MX, Hua S, Shang QY (2021) Application
of nanotechnology in drug delivery systems for
respiratory diseases. Mol Med Rep 23(5):1–7
64. Alonso MJ (2004) Nanomedicines for overcoming biological barriers. Biomed Pharmacother 58(3):168–172
65. Jordan C, V Shuvaev V, Bailey M, R
Muzykantov V, D Dziubla T (2016) The role
of carrier geometry in overcoming biological
barriers to drug delivery. Curr Pharm Des
22(9):1259–1273
66. Awais M, Batool S, Khan M, Asim L, Riaz R,
Zafar R (2023) Strategies for crossing
biological barriers in drug delivery. Proc Natl
Acad Sci, India Sect B 29:1–9
67. Betancourt T, Doiron A, Homan KA,
Brannon-Peppas L (2009) Controlled release
and nanotechnology. In: Nanotechnology in
drug delivery, pp 283–312
68. Park K (2014) Controlled drug delivery systems: past forward and future back. J Control
Release 190:3–8
69. Yun YH, Lee BK, Park K (2015) Controlled
Drug Delivery: Historical perspective for the
next generation. J Control Release 219:2–7
675
88 Mounil Mankad et al.
70. Lee JH, Yeo Y (2015) Controlled drug release
from pharmaceutical nanocarriers. Chem Eng
Sci 125:75– 84
71. Gadde S (2015) Multi-drug delivery nanocarriers for combination therapy. MedChemComm 6(11):1916–1929
72. Vizirianakis IS (2011) Nanomedicine and personalized medicine toward the application of
pharmacotyping in clinical practice to improve
drug-delivery outcomes. Nanomedicine 7(1):
11–17
73. Ho D, Wang CH, Chow EK (2015) Nanodiamonds: The intersection of nanotechnology,
drug development, and personalized medicine.
Sci Adv 1(7):e1500439
74. Alghamdi MA, Fallica AN, Virzı` N,
Kesharwani P, Pittala` V, Greish K (2022) The
promise of nanotechnology in personalized
medicine. J Personal Med 12(5):673
75. Chouaib R, Sarieddine R, Gali-Muhtasib H
(2020) Nanoparticles as drug delivery systems
for cancer treatment: applications in targeted
therapy and personalized medicine. Nanopart
Drug Deliv Syst Cancer Treat 19:1–22
76. Malik S, Muhammad K, Waheed Y (2023)
Emerging applications of nanotechnology in
healthcare and medicine. Molecules 28(18):
6624
77. Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9):
7442–7447
78. Dwivedi N, Saha P (2022, Jan 1) Uncovering
the limitation of nanodrug delivery system:
Backdrop to the game changer. In: Advances
in nanotechnology-based drug delivery systems (pp 321–342). Elsevier
79. De Jong WH, Borm PJ (2008) Drug delivery
and nanoparticles: applications and hazards.
Int J Nanomedicine 3(2):133–149
80. Naahidi S, Jafari M, Edalat F, Raymond K,
Khademhosseini A, Chen P (2013) Biocompatibility of engineered nanoparticles for drug
delivery. J Control Release 166(2):182–194
81. Rodrigues S, Dionı
´
sio M, Remunan Lopez C,
Grenha A (2012) Biocompatibility of chitosan
carriers with application in drug delivery. J
Func Biomater 3(3):615–641
82. Majuru S, Oyewumi MO (2009) Nanotechnology in drug development and life cycle
management. In: Nanotechnology in drug
delivery, pp 597–619
83. Judefeind A, de Villiers MM (2009) Drug
loading into and in vitro release from nanosized
drug delivery systems. In: Nanotechnology in
drug delivery, pp 129–162
84. Shen S, Wu Y, Liu Y, Wu D (2017) High drugloading nanomedicines: progress, current status, and prospects. Int J Nanomedicine 31:
4085–4109
85. Ruge CA, Kirch J, Lehr CM (2013) Pulmonary
drug delivery: from generating aerosols to
overcoming biological barriers—therapeutic
possibilities and technological challenges. Lancet Respir Med 1(5):402–413
86. Barua
S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across
cell and tissue barriers: a review of current status and future prospects. Nano Today 9(2):
223–243